Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. A Phase 1b/2a study of PIPE-505 in SNHL is expected to begin enrolling patients in 4Q 2019, with topline results expected in late 2020. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remeylation and axonal repair, to address a range of neurological disorders,
